DUBLIN, Feb. 5, 2018 /PRNewswire/ -- Allergan plc
(NYSE: AGN) a leading global biopharmaceutical company, today
announced that Matthew M. Walsh has
been appointed Executive Vice President and Chief Financial
Officer. He will formally join Allergan later this month
following a transition period from his current role as Executive
Vice President, Chief Financial Officer at Catalent, Inc.
"Matt Walsh is an experienced
Chief Financial Officer with a strong track record of creating
value for shareholders, including 14 years as a CFO with three
public companies and ten years in health care as CFO at Catalent
where he led their transformation under private equity, a
successful IPO and numerous acquisition and divestiture
transactions, all while driving sustained organic growth.
Matt brings to Allergan a unique combination of skills, including a
technical background, a deep understanding of the healthcare
industry, a rich experience across financial disciplines, and the
ability to lead complex health care organizations," said
Brent L. Saunders, Chairman and
Chief Executive Officer at Allergan. "I'm pleased to welcome Matt
to our team and look forward to partnering with him as we continue
to drive strong financial performance and deploy our capital to
increase shareholder return over the short- and long-term."
"I'm very excited to join Allergan's fast-paced, results
oriented culture. I look forward to working with Brent and the
leadership team to realize Allergan's long-term growth potential in
the U.S. and internationally, as well as unlocking additional value
through the Open Science R&D pipeline," said Matt Walsh.
Mr. Walsh currently serves as the Executive Vice President and
Chief Financial Officer at Catalent, a role he assumed in 2008.
Prior to joining Catalent, Walsh was President, Chief Financial
Officer and Acting Chief Executive Officer at Escala Group,
Inc. Prior to joining Escala, Walsh held a variety of finance
leadership roles at industrial manufacturer GenTek, Inc., including
Vice President-Finance & Chief Financial Officer, Vice
President & Treasurer and Group Controller.
Mr. Walsh previously served on the board of directors of
Multi-Color Corporation from 2015 to 2017 and Escala Group, Inc.
from 2006 to 2008. While on the board of Multi-Color
Corporation, he also served as Audit Committee Chairman.
Walsh is a CFA® charterholder who received a MBA from
Cornell University, SC Johnson Graduate
School of Management, and a Bachelor of Science in Chemical
Engineering from Cornell University,
College of Engineering.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues'
commitment to being Bold for Life. Together, we build bridges,
power ideas, act fast and drive results for our customers and
patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; uncertainty
associated with financial projections, projected cost reductions,
projected synergies, restructurings, increased costs, and adverse
tax consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2016
and Allergan's Quarterly Report on Form 10-Q for the period ended
September 30, 2017. Except as
expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS:
Allergan:
Investors:
Daphne
Karydas
(862) 261-8006
Media:
Lisa Brown
(862) 261-7320
View original content with
multimedia:http://www.prnewswire.com/news-releases/matthew-m-walsh-appointed-executive-vice-president-and-chief-financial-officer-of-allergan-plc-300593303.html
SOURCE Allergan plc